Clinical Trial Update: A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer [Phase 4]

View source ↗

Summary

Phase 4 study evaluating bevacizumab with taxane therapy in triple-negative breast cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Taxane therapy (taxane)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 4 | Status: COMPLETED | Results posted: 2018-03-22